INmune Bio Projects Cash Runway Extends Through Q1 2027
Summary
INmune Bio announced that its current cash on hand is estimated to provide a financial runway through the first quarter of 2027. This update on liquidity is significant for a small-cap biotechnology company, as it provides clarity on its ability to fund ongoing operations and clinical development without immediate capital raises. This follows recent positive news on March 19, 2026, regarding the company's Phase 2 MINDFuL trial for XPro™ in early Alzheimer's disease. Investors will now monitor the company's progress in its clinical programs and any future updates on its financial position as it approaches the end of this estimated runway.
At the time of this announcement, INMB was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.3M. The 52-week trading range was $1.10 to $11.64. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.